Skip to main content

CombiMatrix - Fundamentalanalyse - Jahresbericht / Bilanz / Geschäftsbericht

CombiMatrix (ISIN: US20009T5011, WKN: A2AD52) Kursdatum: 27.07.2017 Kurs: 5,180 USD
Beschreibung Daten
Symbol CBMX
Marktkapitalisierung 13.260.800,00 USD
Land Vereinigte Staaten von Amerika
Indizes NASDAQ Comp.
Sektor Konsumgüter
Rohdaten nach US GAAP in Millionen USD
Aktiensplits 2016-02-01 - 1:15 | 2012-12-05 - 1:10 | 2007-08-15 - 1:10 |
Internet
Letztes Bilanz Update 03.03.2017

Fundamentaldaten

Fundamental Verhältnisse errechnet am: 27.07.2017
KFCV KCV DIV Rendite GKR EKQ KGV KUV KBV
-3,27 -3,40 0,00% -98,74 76,60 -1,58 1,03 2,04

Firmenbeschreibung

Firmenstrategie

Basis of Presentation and Principles of Consolidation. The accompanying consolidated financial statements include the accounts of the Company and our wholly owned subsidiaries. Investments for which we possess the power to direct or cause the direction of the management and policies, either through majority ownership or other means, are accounted for under the consolidation method. Material intercompany transactions and balances have been eliminated in consolidation. Investments in companies in which we maintain an ownership interest of 20% to 50% or exercise significant influence over operating and financial policies are accounted for under the equity method. The cost method is used where we maintain ownership interests of less than 20% and do not exercise significant influence over the investee.

RevenueRecognitionPolicyTextBlock

Revenue Recognition

. We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured.

 

Service revenues from providing diagnostic tests are recognized when the testing process is complete and test results are reported to the ordering physician or clinic. These diagnostic services are billed to various payors, including commercial insurance companies, healthcare institutions, government payors including various state Medicaid programs, and individuals. We report revenues from contracted payors based on a contractual rate, or in the case of state Medicaid contracts, published fee schedules for our tests. We report revenues from non-contracted payors based on the amounts expected to be collected. The differences between the amounts billed and the amounts expected to be collected from non-contracted payors are recorded as contractual allowances to arrive at net recognized revenues. The expected revenues from non-contracted payors are based on the historical collection experience of each payor or payor group, as appropriate, and also take into account recent collection trends. In each reporting period, we review our historical collection experience for non-contracted payors and adjust our expected revenues for current and subsequent periods accordingly. We also recognize additional revenue from actual cash payments that exceed amounts initially recognized, in the period the payments are received. For the years ended December 31, 2015 and 2014, net positive revenue adjustments were $580,000 and $381,000, respectively. Because a substantial portion of our revenues is from non-contracted third-party payors, it is likely that we will be required to make adjustments to accounting estimates with respect to contractual allowances in the future, which may positively or adversely affect our results of operations. In all cases described above, we report revenues net of any applicable statutory taxes collected from customers, as applicable. For the years ended December 31, 2015 and 2014, no single customer represented 10% or more of our revenues.         

SegmentReportingDisclosureTextBlock

EarningsPerSharePolicyTextBlock

Net Loss Per Share

. Basic and diluted net loss per share has been computed by dividing the net loss by the weighted average number of common shares issued and outstanding during the periods presented. Options and warrants to purchase CombiMatrix stock as well as preferred stock convertible into shares of common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share. The following table reflects the excluded dilutive securities:

 

 

 
 
 
For the Years Ended
 
December 31,
 
 
 
 
2015
 
 
 
2014
 
                 
 
Common stock options
    69,995       46,060  
 
Restricted stock units
    38,795       20,181  
 
Common stock warrants
    643,317       493,927  
 
Series E preferred stock convertible into common stock
    83,871       -  
 
Excluded potentially dilutive securities
    835,978       560,168